TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma

URN to cite this document:: urn:nbn:de:bvb:355-epub-535826
DOI to cite this document:: 10.5283/epub.53582

Eichberger, Jonas ; Spoerl, Silvia ; Spanier, Gerrit

; Erber, Ramona ; Taxis, Juergen

; Schuderer, Johannes ; Ludwig, Nils

; Fiedler, Mathias ; Nieberle, Felix ; Ettl, Tobias

; Geppert, Carol I. ; Reichert, Torsten E. ; Spoerl, Steffen

License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 20 Jan 2023 05:51

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background: T-cell immunoglobulin and ITIM domain (TIGIT) is a potential immunotherapeutic target in a variety of malignant entities, and antibody-based treatments are currently under investigation in clinical trials. While promising results were observed in patients with lung cancer, the role of TIGIT in oral squamous cell carcinoma (OSCC) as a biomarker as well as a therapeutic target remains ...